Pilot Study of the IL-1 Antagonist Anakinra for the Treatment of Endometriosis Related Symptoms
Status:
Recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
All current FDA approved medications to treat endometriosis pain including danazol, GnRH
agonists (Lupron, Zoladex and Synarel), GnRH antagonist (elagolix) and depo-provera prevent
or contradict pregnancy. Therefore women suffering from endometriosis and trying to conceive
have no medical options apart from pain meds. The purpose of this pilot study is to determine
whether the anti-inflammatory, IL-1 inhibitor (anakinra) reduces pelvic pain due to
endometriosis without altering menstrual cycles, which is an indicator of ovulatory function.
Anakinra is an FDA approved injectable medication for the treatment of rheumatoid arthritis
that is pregnancy category B.
Phase:
Early Phase 1
Details
Lead Sponsor:
University of California, San Diego
Treatments:
Citric Acid Interleukin 1 Receptor Antagonist Protein